GILD - Gilead Sciences

-

$undefined

N/A

(N/A)

Gilead Sciences NASDAQ:GILD Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead has promoted equity, particularly healthcare equity, since the company brought its first therapies to the market. Through global partnerships, Gilead's medicines today reach millions of people in low- and middle-income countries around the world. In the United States, Gilead has committed more than $100 million over 10 years through the COMPASS Initiative to community organizations that are working to combat HIV in the Southern United States. In 2020, Gilead launched the Racial Equity Community Impact Fund to support organizations tackling racial inequities affecting Black communities across the United States.

Location: 333 Lakeside Dr, California, 94404-1147, US | Website: www.gilead.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

129.1B

Cash

3.781B

Avg Qtr Burn

N/A

Short % of Float

1.33%

Insider Ownership

0.12%

Institutional Own.

87.91%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Tecartus® (brexucabtagene autoleucel) (CAR-T) Details
B-cell acute lymphoblastic leukemia, Acute lymphoblastic leukemia, Leukemia

Approved

Quarterly sales

Yescarta® Details
B-cell lymphoma, Lymphopenia

Approved

Quarterly sales

Livdelzi (Seladelpar) Details
Primary biliary cholangitis, Primary sclerosing cholangitis, Non-alcoholic steatohepatitis , Liver disease

Approved

Quarterly sales

Trodelvy® (sacituzumab govitecan-hziy) Details
Breast cancer, ER+/HER2- breast cancer, Cancer

Approved

Quarterly sales

Biktarvy Details
Human immunodeficiency virus

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Phase 3

Update

Phase 3

Update

Lenacapavir Details
Human immunodeficiency virus

Phase 3

Update

Anito-cel Details
Multiple myeloma

Phase 3

Initiation

Sunlenca (Lenacapavir) Details
Human immunodeficiency virus

Phase 2/3

Data readout

Phase 2b

Update

Phase 2

Update

Phase 2

Update

Etrumadenant Details
Colorectal cancer

Phase 2

Update

Yescarta Details
Lymphopenia, B-cell lymphoma

Phase 2

Update

Magrolimab+Azacitidine Details
High risk myelodysplastic syndromes

Failed

Discontinued